| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 06/16/2005 | US20050130920 Promotes a prolonged, directed cytotoxic T cell response to the target cell; cancer; vaccine |
| 06/16/2005 | US20050130918 Respiratory disorders, inflammatory disorders, allergy, or asthma |
| 06/16/2005 | US20050130899 Tumor antigens |
| 06/16/2005 | US20050130886 Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit |
| 06/16/2005 | US20050130244 for detection of 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA) anibody production; drug screening; haptens; immunogens |
| 06/16/2005 | US20050130243 For detection of 3,4-methylenedioxyamphetamine (MDA), 3,4-methylenedioxy-methamphetamine (MDMA) anibody production; drug screening; haptens; immunogens; kits |
| 06/16/2005 | US20050130242 Uses of aldose-1-epimerase (mutarotase) for diagnosis and therapy of inflammatory diseases and sepsis |
| 06/16/2005 | US20050130225 Ecstasy haptens and immunogens |
| 06/16/2005 | US20050130166 Cloning, sequencing and expression of a gene encoding an eukaryotic amino acid racemase, and diagnostic, therapeutic, and vaccination applications of parasite and viral mitogens |
| 06/16/2005 | US20050130154 Compositions and methods relating to endometrial specific genes and proteins |
| 06/16/2005 | US20050130146 Histone deactylase for use in identifying modulators for prevention and treatment of cell proliferative disorders |
| 06/16/2005 | US20050130135 Hepatitis a virus nucleotide sequences, recombinant proteins and uses thereof |
| 06/16/2005 | US20050130132 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| 06/16/2005 | US20050130130 Killer cell activatory receptor ligand for use in diagnosis, prevention and treatment of infection, cell proliferative, autoimmune and arthritic disorders |
| 06/16/2005 | US20050130127 Coronavirus-like particles comprising functionally deleted genomes |
| 06/16/2005 | US20050130125 End of aids for general virology, based on profound science as protein foldings: safe vaccines, universal antimicrobial means, mad cow end |
| 06/16/2005 | US20050129751 Controlled release of drug |
| 06/16/2005 | US20050129717 Novel uses |
| 06/16/2005 | US20050129715 Methods and compositions for immunotherapy of cancer |
| 06/16/2005 | US20050129714 Vaccine against salmonid rickettsial septicaemia based on arthrobacter cells |
| 06/16/2005 | US20050129713 For use in vaccine |
| 06/16/2005 | US20050129712 Combined dna/protein vaccine compositions |
| 06/16/2005 | US20050129711 Incapacitated whole-cell immunogenic bacterial compositions produced by recombinant expression |
| 06/16/2005 | US20050129707 Vaccine comprising a polysaccharide antigen - carrier protein conjugate and free carrier protein |
| 06/16/2005 | US20050129705 hepatitis C virus; for activating cytotoxic t lymphocytes in presence of major histomcompatibility complex |
| 06/16/2005 | US20050129704 An immunogenic complex that includes plant cells transformed with a chimeric gene containing a nucleotide sequence adapted for protein expression in plants and an RSV coding sequence that encodes an antigenic protein of RSV |
| 06/16/2005 | US20050129703 identifying T cells in a sample that become activated in the presence of a vaccinia or variola virus using immunogenic mutant or fragment of peptide 165 as a CD8 T cell epitope |
| 06/16/2005 | US20050129701 Antibody to latent membrane proteins and uses thereof |
| 06/16/2005 | US20050129700 comprises antibodies against Smallpox Inhibitor of Complement Enzyme (SPICE) or Vaccinia Virus Complement Control Protein (VCP); dna vaccines |
| 06/16/2005 | US20050129699 Tumor necrosis factor (TNF)-related apoptosis-inducing ligands; anticarcinogenic and antiproliferative agents; graft versus host disease, AIDS, neurodegenerative disorders |
| 06/16/2005 | US20050129696 Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids |
| 06/16/2005 | US20050129691 Using A beta antibody antagonist eg immunoglobulin; obsessive-compulsive disorder, panic disorder, panic attack, agoraphobia, post-traumatic stress disorder, social phobia, disruptive behavior disorder, and chronic fatigue syndrome |
| 06/16/2005 | US20050129689 Method for treatment of tumors using photodynamic therapy |
| 06/16/2005 | US20050129688 Monkey monoclonal antibodies specific to human B7.1 and/or B7.2 primatized forms thereof, pharmaceutical compositions containing, and use thereof as immunosuppressants |
| 06/16/2005 | US20050129686 Use of NOTCH pathway interfering agents for treatment of plasma cell disorders |
| 06/16/2005 | US20050129684 Administering an apoptosis inhibitor to a mammal having an eye with retinal detachment |
| 06/16/2005 | US20050129682 Receptor for Advanced Glycation Endproducts (RAGE); rheumatoid arthritis; solubility |
| 06/16/2005 | US20050129681 Inhibiting endothelial cell adhesion and migration; limit specific binding of integrin alpha 4 beta 1; antitumor |
| 06/16/2005 | US20050129680 Antimicrobial activity of antibodies |
| 06/16/2005 | US20050129679 By use of antagonists to JAM-1 Claudin-4 and occludin; drug delivery |
| 06/16/2005 | US20050129678 Using computer modeling to postulate amino acid composition of protein binding sites; bioinformatic and rational drug design |
| 06/16/2005 | US20050129676 Compounds and methods for modulating functions of classical cadherins |
| 06/16/2005 | US20050129671 Mammalian antigen-presenting T cells and bi-specific T cells |
| 06/16/2005 | US20050129657 Interferon-alpha induced gene |
| 06/16/2005 | US20050129617 Contacting a T lymphocyte from the patient with a diagnostic epitope of an amino acid string including hydrophilic amino acids and one of Leucine, Methionine, Isoleucine, Phenylalanine, Alanine, Glycine, Valine, or Tryptophan |
| 06/16/2005 | US20050129616 Antibodies that immunospecifically bind to TRAIL receptors |
| 06/16/2005 | DE10353175A1 Humaner monoklonaler Antikörper mit fettsenkender Wirkung Human monoclonal antibodies with fat-reducing |
| 06/16/2005 | DE10351627A1 Modulation der Angiogenese durch Bartonella henselae Modulation of angiogenesis by Bartonella henselae |
| 06/16/2005 | CA2548942A1 Anti-sars monoclonal antibodies |
| 06/16/2005 | CA2548582A1 Use of gene ncsag4 for the diagnosis and prevention of neosporosis and as a marker for analysis of the pathogenesis |
| 06/16/2005 | CA2548456A1 Combination therapy |
| 06/16/2005 | CA2548454A1 Medicament comprising recombinant antibody against chemokine receptor ccr4 |
| 06/16/2005 | CA2548135A1 Synthetic hla binding peptide analogues and uses thereof |
| 06/16/2005 | CA2547537A1 Protein nmb0928 and use thereof in pharmaceutical formulations |
| 06/16/2005 | CA2547355A1 Animal models of pancreatic adenocarcinoma and uses therefor |
| 06/16/2005 | CA2547317A1 Protein nmb1125 and use thereof in pharmaceutical formulations |
| 06/16/2005 | CA2547016A1 Humanized antibodies against vascular endothelial growth factor |
| 06/16/2005 | CA2547008A1 New class of gamma delta t cells activators and use thereof |
| 06/16/2005 | CA2546710A1 Local intraosseous administration of bone forming agents and anti-resorptive agents, and devices therefor |
| 06/16/2005 | CA2546680A1 Promoters for expression in modified vaccinia virus ankara |
| 06/16/2005 | CA2546452A1 Recombinant adenylate cyclase toxin of bordetella induces t cell responses against tumoral antigens |
| 06/16/2005 | CA2546017A1 Use of notch pathway interfering agents for treatment of plasma cell disorders |
| 06/16/2005 | CA2528182A1 Antibodies specific for cancer associated antigen sm5-1 and uses thereof |
| 06/15/2005 | EP1542012A1 Antibodies for detecting efavirenz |
| 06/15/2005 | EP1541689A2 Hybrid proteins which form heterodimers |
| 06/15/2005 | EP1541684A1 Smg-1-binding protein and method of screening substance controlling its activity |
| 06/15/2005 | EP1541675A2 Hybrid cells obtainable from antigen presenting cells |
| 06/15/2005 | EP1541587A2 Method for down-regulating osteoprotegerin ligand activity |
| 06/15/2005 | EP1541170A1 Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide |
| 06/15/2005 | EP1541165A1 Method of stabilizing protein solution preparation |
| 06/15/2005 | EP1541132A1 Vaccine composition, method of preparing the composition and method of vaccinating vertebrates |
| 06/15/2005 | EP1541036A1 Algae feeds for aquaculture and agriculture |
| 06/15/2005 | EP1540627A2 Immunotherapeutic compositions and methods for the treatment of moderately to well-differentiated cancers |
| 06/15/2005 | EP1540559A2 Bioinformatic method for identifying surface-anchored proteins from gram-positive bacteria and proteins obtained thereby |
| 06/15/2005 | EP1540333A2 Maxs as modifiers of the axin pathway and methods of use |
| 06/15/2005 | EP1539990A2 PSMCs AS MODIFIERS OF THE RB PATHWAY AND METHODS OF USE |
| 06/15/2005 | EP1539978A1 Method of isolating biologically active fraction containing clinically acceptable native slipopolysaccharides obtained from bacteria producing endotoxic lipopolysaccharides |
| 06/15/2005 | EP1539977A2 Tiacumicin production |
| 06/15/2005 | EP1539974A1 Orthopoxvirus vectors, genes and products thereof |
| 06/15/2005 | EP1539971A1 Her-2/neu dna vaccine having anti-cancer activity |
| 06/15/2005 | EP1539968A2 Plastid genetic engineering via somatic embryogenesis |
| 06/15/2005 | EP1539944A2 Methods and compositions for the identification of antibiotics that are not susceptible to antibiotic resistance |
| 06/15/2005 | EP1539942A2 Nucleic acid molecules encoding a transmembrane serine protease 10, the encoded polypeptides and methods based thereon |
| 06/15/2005 | EP1539937A2 Methods for propagating adenovirus and virus produced thereby |
| 06/15/2005 | EP1539820A2 Ostertagia vaccine |
| 06/15/2005 | EP1539819A2 Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells |
| 06/15/2005 | EP1539813A2 Polypeptides and nucleic acids encoding these and their use for the prevention, diagnosis or treatment of liver disorders and epithelial cancer |
| 06/15/2005 | EP1539811A2 Production of bispecific molecules using polyethylene glycol linkers |
| 06/15/2005 | EP1539810A1 Immunogenic polypeptide isolated from mycobacterium avium subspecies paratuberculosis and uses thereof |
| 06/15/2005 | EP1539809A2 Hcv fusion proteins with modified ns3 domains |
| 06/15/2005 | EP1539808A2 gM-NEGATIVE EHV-MUTANTS WITHOUT HETEROLOGOUS ELEMENTS |
| 06/15/2005 | EP1539805A2 Nucleic acids and corresponsing proteins entitled 101p3a11 or phor-1 useful in treatment and detection of cancer |
| 06/15/2005 | EP1539793A2 Humanized anti-lymphotoyin beta receptor antibodies |
| 06/15/2005 | EP1539785A2 Gene regulation in transgenic animals using a transposon-based vector |
| 06/15/2005 | EP1539247A2 Alpha 5 beta 1 and its ability to regulate the cell survival pathway |
| 06/15/2005 | EP1539241A2 Method of controlling pharmacokinetics of immunomodulatory compounds |
| 06/15/2005 | EP1539239A2 A novel stable formulation |
| 06/15/2005 | EP1539237A2 Humanized antibodies against human 4-1bb |
| 06/15/2005 | EP1539236A2 Compositions, methods and kits relating to anti-platelet autoantibodies and inhibitors thereof |
| 06/15/2005 | EP1539235A2 Antibodies that specifically bind to reg iv |